A room full of oncologists gave a 42-second standing ovation for a single drug trial result. When was the last time you heard of that happening at a medical conference?

The breakthrough that made scientists cheer out loud

I believe this is one of the most important cancer stories in a decade, and it is being criminally underreported outside specialist circles. Daraxonrasib, an oral daily pill developed by Revolution Medicines, nearly doubled survival in patients with metastatic pancreatic cancer compared to standard chemotherapy. That is not a rounding error. That is a seismic shift.

Pancreatic cancer has a 5-year survival rate of roughly 3% for metastatic disease. For more than four decades, the KRAS gene mutation driving roughly 90% of these tumors was labeled "undruggable." Scientists at Dana-Farber Cancer Institute cracked it. The RASolute 302 phase 3 trial showed median overall survival jumping from 6.7 months on chemotherapy to 13.2 months on daraxonrasib.

The drug also cut the risk of death by 60% compared to chemotherapy, with fewer serious side effects. Treatment discontinuation due to adverse events was 1.2% on daraxonrasib versus 11.2% on chemo.

“The RAS revolution is here, and this study is proof of principle that targeting KRAS in pancreatic cancer is feasible and effective.”

— Dr. Rachna Shroff, University of Arizona Cancer Center, ASCO Expert

Why the politics of this moment are genuinely terrifying

Here is where the story turns ugly. The same week oncologists were cheering in Chicago, the political machinery in Washington was busy gutting the infrastructure that produces breakthroughs like this one.

The Trump administration's proposed FY2026 budget calls for a nearly 40% cut to the National Cancer Institute, dropping its budget from $7.22 billion in 2025 to an estimated $4.10 billion. At the NCI, the odds of winning a research grant have already collapsed from 1 in 10 applicants to 1 in 25.

I remember reading about the Cancer Moonshot years ago and thinking: finally, a political commitment that matches the scale of the problem. What we are watching now is the opposite of that.

The counterargument, and why it does not hold up

Some will argue that daraxonrasib was funded by Revolution Medicines, a private company, so federal cuts are irrelevant here. That argument is lazy and wrong.

The foundational science that identified the KRAS binding pocket, the basic biology of RAS mutations, the early clinical trial infrastructure: all of it was built on decades of publicly funded research. Private companies do not invent from scratch. They commercialize what public science makes possible.

The American Cancer Society Cancer Action Network put it plainly: NCI-supported clinical trials between 1980 and 2020 added an estimated 14.2 million additional life-years to cancer patients. You do not slash that pipeline and expect the breakthroughs to keep coming.

What the science actually got right this time

Let me be clear about what deserves genuine praise here. The RASolute 302 trial enrolled 500 patients and compared daraxonrasib head-to-head against real-world chemotherapy options. This was not a cherry-picked surrogate endpoint study. It was a rigorous, randomized phase 3 trial published simultaneously in the New England Journal of Medicine.

The drug also improved quality of life. It delayed time to pain deterioration to a median of 9.2 months versus 3.8 months on chemotherapy. That matters enormously. Surviving longer while feeling worse is not a victory. Surviving longer while feeling better is.

On May 1, 2026, the FDA granted expanded access to daraxonrasib for previously treated patients even before full approval. That is the regulatory system working as it should, moving fast when the evidence is overwhelming.

Science wins. Politics could still lose it for everyone.

The tension here is almost unbearable to sit with. Science just delivered one of its finest hours in oncology. The political environment surrounding it is one of the most hostile to research funding in modern American history.

The next daraxonrasib is sitting in a lab somewhere right now, waiting for a grant that may never come. A young researcher who would have spent 30 years cracking the next "undruggable" target is already looking for a different career because the NCI's funding rate dropped from 9% to 4%.

This is not abstract. Pancreatic cancer kills roughly 50,000 Americans every year. The people who will die from it in 2035 or 2040 are depending on research that needs to start now, funded now, by a government that currently seems determined to walk away.

“Slashing federal research funding at a time when science is revolutionizing cancer care risks leaving millions of patients without the promise of life-saving breakthroughs.”

— ASCO CEO Clifford Hudis, MD, statement on FY2026 budget cuts

The standing ovation in Chicago lasted 42 seconds. The damage from these funding cuts will last decades. Tell me that trade-off is acceptable.